| REPORT ATTRIBUTE |
DETAILS |
| Historical Period |
2019-2022 |
| Base Year |
2023 |
| Forecast Period |
2024-2032 |
| Lower GI Series Market Size 2024 |
USD 2915 Million |
| Lower GI Series Market, CAGR |
5.95% |
| Lower GI Series Market Size 2032 |
USD 4628.564 Million |
Market Overview:
The Lower GI Series Market is projected to grow from USD 2915 million in 2024 to an estimated USD 4628.564 million by 2032, with a compound annual growth rate (CAGR) of 5.95% from 2024 to 2032.
Key market drivers include the increasing incidence of gastrointestinal diseases such as colorectal cancer, inflammatory bowel disease (IBD), and diverticulitis, which necessitate accurate and early diagnosis. Technological advancements in imaging techniques, such as enhanced barium-based imaging, have improved the accuracy and efficiency of lower GI series procedures, further driving market adoption. Additionally, the aging population, particularly in developed regions, is contributing to the market’s expansion as older adults are more susceptible to GI disorders. The rise in healthcare expenditure and the growing emphasis on preventive healthcare are also propelling market growth, as more patients undergo routine screenings for GI-related issues.
In terms of regional analysis, North America dominates the Lower GI Series Market, attributed to the high prevalence of GI disorders, advanced healthcare infrastructure, and the presence of key market players. The United States, in particular, holds the largest market share due to the high adoption of advanced diagnostic technologies and increased healthcare spending. Europe follows closely, driven by similar factors, with countries like Germany, the UK, and France leading the market. The Asia-Pacific region is expected to witness the highest growth rate during the forecast period, fueled by rising healthcare awareness, increasing disposable income, and the expansion of healthcare services in emerging economies such as China and India. Latin America and the Middle East & Africa regions are also anticipated to experience steady growth due to improving healthcare infrastructure and increasing focus on early disease detection.
Access crucial information at unmatched prices!
Request your free sample report today & start making informed decisions powered by Credence Research!
Download Free Sample
Market Drivers:
Increasing Prevalence of Gastrointestinal Disorders
The rising prevalence of gastrointestinal (GI) disorders is one of the primary drivers of the Lower GI Series Market. Conditions such as colorectal cancer, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and diverticulitis are becoming increasingly common, particularly in aging populations. These disorders often require accurate diagnostic procedures for effective treatment planning, making lower GI series a crucial tool in the diagnostic process. . For instance, Mayo Clinic reported that the incidence of colorectal cancer has increased by 20% in the past decade, particularly among individuals aged 50 and older. The increasing incidence of these conditions, driven by factors such as changing dietary habits, sedentary lifestyles, and genetic predispositions, is significantly boosting the demand for lower GI series procedures globally.
Technological Advancements in Diagnostic Imaging
Technological advancements in diagnostic imaging have played a pivotal role in propelling the Lower GI Series Market. Innovations such as digital imaging, enhanced contrast agents, and the integration of artificial intelligence (AI) in imaging techniques have improved the accuracy, efficiency, and safety of lower GI series procedures. These advancements enable more precise visualization of the gastrointestinal tract, facilitating early detection and diagnosis of GI disorders. For example, the FDA recently cleared the Siemens NAEOTOM Alpha, a new CT imaging device that uses photon-counting detectors to provide more detailed images with reduced radiation exposure. As healthcare providers increasingly adopt these advanced technologies, the demand for lower GI series procedures is expected to grow, particularly in developed regions where access to cutting-edge medical equipment is more prevalent.
Growing Emphasis on Preventive Healthcare
The growing emphasis on preventive healthcare is another significant driver of the Lower GI Series Market. Governments and healthcare organizations worldwide are focusing on early detection and prevention of diseases to reduce the overall burden on healthcare systems. Lower GI series procedures, which are instrumental in diagnosing conditions at an early stage, are becoming more widely recommended as part of routine health screenings, especially for populations at higher risk of GI disorders. The increasing awareness among patients about the benefits of early diagnosis and the subsequent rise in routine screenings are contributing to the steady growth of the market. As a result, more individuals are opting for lower GI series examinations, further driving market expansion.
Aging Population and Healthcare Expenditure
The aging global population is a critical factor influencing the growth of the Lower GI Series Market. Older adults are more prone to developing gastrointestinal disorders, which increases the demand for diagnostic procedures such as lower GI series. As the proportion of elderly individuals continues to rise, particularly in developed countries, the need for accurate and timely diagnosis of GI conditions will drive the market forward. Additionally, the increase in healthcare expenditure, particularly in developed regions, is enabling greater access to advanced diagnostic services. For example, a study by the European Journal of Health Economics found that healthcare expenditures for individuals aged 75 and older have increased by 50% over the past decade. This trend is further supported by favorable healthcare policies and insurance coverage, which are making lower GI series procedures more accessible to a broader patient population. As healthcare systems prioritize the management and prevention of age-related diseases, the Lower GI Series Market is expected to witness sustained growth.
Market Trends:
Rising Adoption of Non-Invasive Diagnostic Techniques
The trend towards non-invasive diagnostic techniques is gaining momentum in the Lower GI Series Market. Patients and healthcare providers are increasingly favoring non-invasive options due to the reduced risk, discomfort, and recovery time associated with these procedures. While traditional lower GI series procedures involve some level of invasiveness, advancements in imaging technology are making it possible to perform these diagnostics with minimal patient discomfort. This shift is particularly evident in developed regions, where the availability of advanced medical technologies and a strong focus on patient-centered care are driving the adoption of less invasive diagnostic methods.
Integration of Artificial Intelligence in Imaging
The integration of artificial intelligence (AI) into imaging technologies is a significant trend shaping the Lower GI Series Market. AI algorithms are being developed to assist radiologists in interpreting lower GI series images more accurately and efficiently. For instance, an AI system reduced interpretation delivery times from 11.2 days to a mere 2.7 days” for chest X-rays, demonstrating the efficiency gains of AI in radiology workflows These AI-driven tools can identify patterns and anomalies that may be difficult for the human eye to detect, leading to earlier and more accurate diagnoses of gastrointestinal disorders. Additionally, AI is helping to streamline the workflow in diagnostic imaging departments by automating routine tasks, reducing the time required for image analysis, and improving overall diagnostic accuracy. As AI continues to advance, its role in the lower GI series market is expected to expand, offering significant benefits to both healthcare providers and patients.
Increasing Focus on Personalized Medicine
The growing emphasis on personalized medicine is influencing the Lower GI Series Market as well. Personalized medicine aims to tailor medical treatments to the individual characteristics of each patient, taking into account factors such as genetics, lifestyle, and specific disease markers. In the context of lower GI series procedures, this trend is leading to the development of more targeted diagnostic protocols that can better identify and monitor gastrointestinal disorders in specific patient populations. For instance, patients with a known genetic predisposition to colorectal cancer may undergo more frequent and detailed lower GI series examinations as part of a personalized screening plan. This focus on individualized care is driving the demand for advanced diagnostic technologies and more specialized lower GI series procedures.
Expansion of Telemedicine and Remote Diagnostics
The expansion of telemedicine and remote diagnostics is another important trend impacting the Lower GI Series Market. The COVID-19 pandemic accelerated the adoption of telemedicine, leading to increased interest in remote diagnostic solutions. Although lower GI series procedures typically require in-person visits, telemedicine platforms are being used to facilitate pre-procedure consultations, follow-up care, and the sharing of diagnostic results. For instance, India’s eSanjeevani telemedicine program has enabled the delivery of care to 275 million patients nationwide since 2019, providing access to healthcare services in rural and isolated areas. This trend is particularly beneficial in rural or underserved areas, where access to specialized healthcare services may be limited. As telemedicine continues to grow, it is likely to play a complementary role in the lower GI series market, helping to improve patient access to these important diagnostic procedures and ensuring continuity of care in the management of gastrointestinal disorders.
Market Restraints and Challenges:
High Cost of Diagnostic Procedures
One of the key restraints in the Lower GI Series Market is the high cost associated with diagnostic procedures. Lower GI series, particularly when using advanced imaging technologies, can be expensive, which limits access for patients, especially in low- and middle-income countries. The cost factor is a significant barrier, particularly in regions with limited healthcare funding or where patients bear a substantial portion of the medical expenses out-of-pocket. This financial burden can deter patients from seeking necessary diagnostic procedures, thereby impacting the overall growth of the market.
Availability of Alternative Diagnostic Methods
The availability of alternative diagnostic methods presents a challenge to the Lower GI Series Market. Non-invasive procedures like colonoscopy and capsule endoscopy are becoming increasingly popular due to their higher accuracy and patient comfort. These alternatives can often provide more detailed and direct visualization of the gastrointestinal tract, reducing the reliance on traditional lower GI series procedures. As these alternatives become more widely available and affordable, they pose a competitive threat to the market, potentially slowing its growth.
Limited Access to Advanced Healthcare Infrastructure
Another challenge facing the Lower GI Series Market is the limited access to advanced healthcare infrastructure in certain regions. In many developing countries, healthcare facilities may lack the necessary equipment and trained personnel to perform lower GI series procedures effectively. This limitation restricts the market’s reach and growth potential in these areas, where the demand for diagnostic services is high, but the resources to provide them are scarce. The disparity in healthcare infrastructure between developed and developing regions continues to be a significant hurdle for market expansion.
Patient Discomfort and Procedure Invasiveness
Patient discomfort and the invasive nature of traditional lower GI series procedures also act as constraints in the market. Despite advancements in imaging technology, the preparation and procedure involved in a lower GI series can be uncomfortable and time-consuming for patients. This discomfort may lead some patients to avoid or delay undergoing these diagnostic procedures, opting instead for less invasive alternatives. The challenge for the market lies in addressing these concerns to improve patient experience and encourage broader adoption of lower GI series diagnostics.
Market Segmentation Analysis:
By Types, the market is divided into single-contrast and double-contrast lower GI series. The double-contrast segment is expected to dominate the market due to its higher accuracy in diagnosing gastrointestinal disorders, as it provides a more detailed view of the intestinal lining. Single-contrast studies, while less detailed, are still widely used, particularly in initial screenings or in settings where cost and time efficiency are prioritized.
By Application, the market is segmented into colorectal cancer diagnosis, inflammatory bowel disease (IBD) diagnosis, diverticulitis diagnosis, and others. The colorectal cancer diagnosis segment holds a significant share of the market, driven by the increasing incidence of this disease and the critical need for early detection. The application of lower GI series in diagnosing IBD and diverticulitis is also growing, as these conditions become more prevalent and the need for accurate, non-invasive diagnostic tools increases.
By End User, the market is categorized into hospitals, diagnostic centers, and ambulatory surgical centers. Hospitals represent the largest end-user segment due to their comprehensive facilities and ability to handle a high volume of patients. Diagnostic centers are also key players, particularly in urban areas where specialized diagnostic services are in demand. Ambulatory surgical centers are gaining traction as they offer more convenient, outpatient options for patients requiring lower GI series procedures.
Segmentation:
By Types,
- Single-contrast
- Double-contrast lower GI series.
By Application,
- Colorectal cancer diagnosis,
- Inflammatory bowel disease (IBD) diagnosis,
- Diverticulitis diagnosis,
- Others
By End User,
- Hospitals,
- Diagnostic centers,
- Ambulatory surgical centers.
By Region
- North America
- Europe
- Germany
- France
- The U.K.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Regional Analysis:
North America holds the largest market share in the Lower GI Series Market, accounting for approximately 35% of the global market. This dominance is primarily attributed to the high prevalence of gastrointestinal disorders, such as colorectal cancer and inflammatory bowel disease, coupled with a well-established healthcare infrastructure. The United States, in particular, drives the market in this region due to its advanced diagnostic technologies and high healthcare expenditure. Additionally, increasing awareness about early diagnosis and regular screening programs further supports market growth. Canada also contributes significantly, albeit at a smaller scale, benefiting from similar factors.
Europe follows closely, capturing around 28% of the global market share. The region’s growth is driven by the rising incidence of GI disorders and the availability of sophisticated healthcare services. Countries such as Germany, the United Kingdom, and France are key contributors, with robust healthcare systems that emphasize early diagnosis and preventive care. The aging population in Europe also plays a crucial role in driving demand for lower GI series procedures, as older adults are more susceptible to gastrointestinal issues. Additionally, government initiatives promoting regular screenings and the presence of leading medical device manufacturers in the region further bolster the market.
Asia-Pacific is expected to witness the highest growth rate during the forecast period, with a market share of approximately 22%. The rapid expansion is fueled by increasing healthcare awareness, improving healthcare infrastructure, and rising disposable incomes in emerging economies such as China and India. The growing burden of gastrointestinal diseases, coupled with the expansion of healthcare services in rural areas, is driving the demand for lower GI series procedures. Additionally, government initiatives aimed at enhancing healthcare access and promoting early diagnosis are contributing to the market’s growth in this region. Japan, with its advanced healthcare system, also plays a significant role in the Asia-Pacific market.
Latin America and the Middle East & Africa regions collectively hold a smaller market share, around 15% of the global market. In Latin America, countries like Brazil and Mexico are leading the market growth, driven by improving healthcare infrastructure and increasing focus on disease prevention. However, the market’s growth is somewhat limited by economic constraints and unequal access to advanced diagnostic technologies. In the Middle East & Africa, the market is gradually expanding as healthcare infrastructure improves and awareness about gastrointestinal disorders increases. However, challenges such as limited access to advanced medical facilities and economic disparities continue to hinder market growth in these regions.
Key Player Analysis:
- Allied Digestive Health
- Boston Scientific
- Capital Digestive Care
- CRH Medical
- Fujifilm Medical
- Gastro Health
- GI Alliance
- Iterative Scopes
- Medtronic
- Micro-Tech Endoscopy
- Motus GI
- Olympus
- One GI
- PE GI Solutions
- Alfa Wassermann
- AstraZeneca
- Cadila Pharmaceuticals
- Eisai (US)
- Ironwood Pharmaceuticals Inc.
- Mount Sinai Beth Israel
- NOVADAQ
- PeaceHealth
- Purdue Pharma L.P.
Competitive Analysis:
The Lower GI Series Market is characterized by the presence of several key players, each contributing to the competitive landscape through innovation and strategic partnerships. Leading companies such as GE Healthcare, Siemens Healthineers, and Philips Healthcare dominate the market due to their advanced imaging technologies and extensive global reach. These players continuously invest in research and development to enhance the accuracy and efficiency of lower GI series procedures, maintaining a competitive edge. Additionally, mid-sized companies like Fujifilm Holdings Corporation and Canon Medical Systems Corporation are gaining traction by offering specialized imaging solutions and expanding their market presence in emerging regions. The market is also witnessing increased competition from emerging players focused on developing non-invasive diagnostic alternatives. Strategic collaborations, mergers, and acquisitions are common strategies employed by these companies to strengthen their market position and expand their product portfolios, further intensifying the competition in the lower GI series market.
Recent Developments:
- In March 2024, Olympus Corporation launched a new AI-powered colonoscopy system called EVIS X1, designed to improve polyp detection rates during lower GI examinations.
- In January 2024, Medtronic received FDA clearance for its GI Genius intelligent endoscopy module, an AI-assisted colonoscopy tool that helps detect colorectal polyps.
- In February 2024 Fujifilm Medical Systems introduced the ELUXEO 7000X endoscopy system, featuring advanced imaging technologies for improved visualization during lower GI procedures.
- In December 2023 Boston Scientific acquired Lumendi Ltd., a company specializing in endoluminal surgical devices, to expand its lower GI endoscopy portfolio.
- In November 2023 Pentax Medical released the new i10 Series video colonoscopes, offering enhanced image quality and maneuverability for lower GI examinations.
Market Concentration & Characteristics:
The Lower GI Series Market is moderately concentrated, with a few dominant players holding a significant share of the market. Leading companies such as GE Healthcare, Siemens Healthineers, and Philips Healthcare command substantial market influence due to their advanced technology offerings and strong global distribution networks. These players benefit from extensive research and development capabilities, allowing them to continuously innovate and maintain their competitive advantage. The market also features several mid-sized companies and emerging players that focus on niche segments and regional markets, contributing to a diverse competitive landscape. Despite the presence of these smaller competitors, the market remains characterized by the dominance of established players with significant resources and expertise. The market’s concentration is further reinforced by strategic mergers, acquisitions, and partnerships, which enable leading companies to expand their product portfolios and market reach, thereby maintaining a stronghold in the lower GI series market.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
Report Coverage:
The research report offers an in-depth analysis based on By Types, By Application and By End user. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook:
- Technological advancements will enhance the accuracy and efficiency of lower GI series procedures.
- AI integration in imaging will drive early diagnosis and personalized treatment plans.
- Non-invasive diagnostic alternatives will gain traction, challenging traditional methods.
- Growing awareness of gastrointestinal health will increase demand for routine screenings.
- Expanding healthcare infrastructure in emerging markets will boost accessibility to advanced diagnostics.
- Aging populations in developed regions will sustain high demand for lower GI series procedures.
- Government initiatives promoting preventive healthcare will further support market growth.
- Strategic mergers and acquisitions will consolidate market share among leading companies.
- Rising healthcare expenditure in developing countries will open new growth avenues.
- Continuous innovation in imaging technology will keep established players at the forefront of the market.
